Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00483756
Registration number
NCT00483756
Ethics application status
Date submitted
6/06/2007
Date registered
7/06/2007
Date last updated
14/03/2013
Titles & IDs
Public title
Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients
Query!
Scientific title
A Phase 2 Randomized, Multicenter, Active Comparator-Controlled Trial to Evaluate the Safety and Efficacy of Co-administration of CP-690,550 and Mycophenolate Mofetil / Mycophenolate Sodium in De Novo Renal Allograft Recipients
Query!
Secondary ID [1]
0
0
A3921030
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Kidney Transplantation
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Cyclosporine
Treatment: Drugs - CP-690,550
Treatment: Drugs - CP-690,550
Active Comparator: 1 - Treatment Arm 1 will also receive standard of care medications
Experimental: 2 - Treatment Arm 2 will also receive standard of care medications
Experimental: 3 - Treatment Arm 3 will also receive standard of care medications
Treatment: Drugs: Cyclosporine
Standard of care
Treatment: Drugs: CP-690,550
CP-690,550 15 mg BID for Months 1-6, then 10 mg BID for Months 7-12
Treatment: Drugs: CP-690,550
CP-690,550 15 mg BID for Months 1-3, then 10 mg BID for Months 4-12
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Participants With First Clinical Biopsy Proven Acute Rejection (BPAR) Episode 6 Months Post-Transplant
Query!
Assessment method [1]
0
0
Clinical BPAR was a BPAR (category acute rejection as interpreted by the central blinded pathologist according to the Banff 97 working classification) associated with an increase in serum creatinine of >= 0.3 milligram per deciliter (mg/dL) and >=20 percent (%) from pre-rejection baseline. The increase in serum creatinine was assessed based on the comparison of baseline and the highest serum creatinine recorded within 24 hours (hrs) of the time of biopsy.
Query!
Timepoint [1]
0
0
Baseline up to Month 6
Query!
Primary outcome [2]
0
0
Glomerular Filtration Rate (GFR) at Month 12
Query!
Assessment method [2]
0
0
GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was calculated using iohexol serum clearance. For determination of iohexol serum clearance, iohexol was administered as an intravenous bolus over 5 minutes immediately after morning dosing of CP-690,550 or CsA on day of GFR evaluation. A normal GFR is greater than (>) 90 milliliter per minute (mL/min), although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR less than (<) 15 mL/min indicated kidney failure.
Query!
Timepoint [2]
0
0
2, 3, 4, and 5 hrs post iohexol intravenous bolus at Month 12
Query!
Secondary outcome [1]
0
0
Glomerular Filtration Rate (GFR) at Month 6
Query!
Assessment method [1]
0
0
GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was calculated using iohexol serum clearance. For determination of iohexol serum clearance, iohexol was administered as an intravenous bolus over 5 minutes immediately after morning dosing of CP-690,550 or CsA on day of GFR evaluation. A normal GFR is >90 mL/min, although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR <15 mL/min indicated kidney failure.
Query!
Timepoint [1]
0
0
2, 3, 4, and 5 hrs post iohexol intravenous bolus at Month 6
Query!
Secondary outcome [2]
0
0
Number of Participants With Progression of Chronic Allograft Lesions at Month 12
Query!
Assessment method [2]
0
0
Progression of chronic allograft lesions was defined as an increase in the Banff chronicity score (Banff-CS) in biopsy from the implantation (baseline) biopsy in a given participant. Banff-CS was the sum of the Banff scores for the 4 chronic basic lesions (allograft glomerulopathy [cg] + interstitial fibrosis [ci] + tubular atrophy [ct] + vascular intimal thickening [cv]).The Banff-CS ranged from 0-12, higher score indicated greater lesions and Month 12 Banff-CS greater than the implantation biopsy score indicated progression of lesions.
Query!
Timepoint [2]
0
0
Month 12
Query!
Secondary outcome [3]
0
0
Number of Participants With First Clinical Biopsy Proven Acute Rejection (BPAR) 12 Months Post Transplant
Query!
Assessment method [3]
0
0
Clinical BPAR was a BPAR (category acute rejection as interpreted by the central blinded pathologist according to the Banff 97 working classification) associated with an increase in serum creatinine of >= 0.3 mg/dL and >=20% from pre-rejection baseline. The increase in serum creatinine was assessed based on the comparison of baseline and the highest serum creatinine recorded within 24 hrs of the time of biopsy.
Query!
Timepoint [3]
0
0
Baseline up to Month 12
Query!
Secondary outcome [4]
0
0
Number of Participants With Treated Clinical Acute Rejection
Query!
Assessment method [4]
0
0
Treated clinical acute rejection was defined as an acute rejection episode that was diagnosed based on local biopsy readout and received anti-rejection treatment.
Query!
Timepoint [4]
0
0
Month 6, 12
Query!
Secondary outcome [5]
0
0
Number of Participants With Combined Banff Rejection Categories (Categories 2, 3, and 4)
Query!
Assessment method [5]
0
0
Banff 97: standard classification for scoring and classifying rejection of kidney transplant biopsies in 6 diagnostic categories: normal, antibody-mediated rejection, borderline changes: 'suspicious' for acute cellular rejection, acute/active cellular rejection, chronic/sclerosing allograft nephropathy, and other. Combined Banff rejection calculated from categories of antibody-mediated rejection (Category 2) plus borderline changes (Category 3) plus acute rejection (Category 4), as interpreted by the central pathologist.
Query!
Timepoint [5]
0
0
Month 6, 12
Query!
Secondary outcome [6]
0
0
Number of Participants With Graft Loss
Query!
Assessment method [6]
0
0
Graft loss was defined as graft nephrectomy, participant death, re-transplantation, or return to dialysis for >=6 consecutive weeks.
Query!
Timepoint [6]
0
0
Month 6, 12
Query!
Secondary outcome [7]
0
0
Number of Participants With Efficacy Failure
Query!
Assessment method [7]
0
0
Efficacy failure was the first occurrence of clinical BPAR diagnosed by the central pathologist or graft loss including participant death.
Query!
Timepoint [7]
0
0
Month 6, 12
Query!
Secondary outcome [8]
0
0
Number of Participants Who Died
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
Month 6, 12
Query!
Secondary outcome [9]
0
0
Lymphocyte Subset
Query!
Assessment method [9]
0
0
The absolute cell counts of cluster of differentiation 3 (CD3): T-lymphocytes, cluster of differentiation 19 (CD19): B-lymphocytes, and cluster of differentiation 56 (CD56): assumed natural killer cells, were determined using flow cytometry.
Query!
Timepoint [9]
0
0
Month 1, 3, 6, 12
Query!
Secondary outcome [10]
0
0
Population Pharmacokinetics (PK)
Query!
Assessment method [10]
0
0
Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.
Query!
Timepoint [10]
0
0
Pre-dose-2(P-2), Pre-dose(P), 0.5,1,2 hr post-dose(PD) on Day14, Month(M) 3; P,1,2 hr PD on M1; P, 0.5, 2, 4 hr PD on M6; P-2, P, 0.5 hr PD on M9, M12 as per randomization in CP-690,550 treated; P on M3 and P, 2, 4 hr PD on M6 in CsA treated participants
Query!
Secondary outcome [11]
0
0
Glomerular Filtration Rate (GFR) by The Nankivell Equation
Query!
Assessment method [11]
0
0
GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was measured directly or estimated using established formulas. GFR was calculated was estimated by creatinine clearance (CLcr) using Nankivell equation. CLcr by Nankivell equation= (6.7 per serum creatinine) plus (0.25*body weight) minus (0.5*serum urea) minus (100 per height square) plus (35 for male/25 for female). A normal GFR is >90 mL/min, although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR <15 mL/min indicated kidney failure.
Query!
Timepoint [11]
0
0
Month 1, 3, 6, 9, 12
Query!
Secondary outcome [12]
0
0
Glomerular Filtration Rate (GFR) by The Cockcroft-Gault Equation
Query!
Assessment method [12]
0
0
GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was measured directly or estimated using established formulas. GFR was calculated using Cockcroft-Gault equation. GFR by Cockcroft-Gault equation= body weight*(140 minus age in years) divided by (72*serum creatinine). For females value obtained was multiplied by 0.85. A normal GFR is >90 mL/min, although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR <15 mL/min indicated kidney failure.
Query!
Timepoint [12]
0
0
Month 1, 3, 6, 9, 12
Query!
Secondary outcome [13]
0
0
Glomerular Filtration Rate (GFR) by The Modification of Diet in Renal Disease (MDRD) Equation
Query!
Assessment method [13]
0
0
GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was calculated using MDRD equation. GFR by MDRD equation = 170 * (serum creatinine)^(-0.999) * (age in years)^(-0.176) * (0.762 if female) * (1.18 if black) * (blood urea nitrogen concentration)^(-0.170) * (serum albumin concentration)^(0.318).A normal GFR is >90 mL/min/1.73 square meter (m^2), although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR <15 mL/min/1.73 m^2 indicated kidney failure.
Query!
Timepoint [13]
0
0
Month 1, 3, 6, 9, 12
Query!
Secondary outcome [14]
0
0
Glomerular Filtration Rate (GFR) by The Abbreviated Modification of Diet in Renal Disease (MDRD) Equation
Query!
Assessment method [14]
0
0
GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was measured directly or estimated using established formulas. GFR was calculated using abbreviated MDRD equation. GFR by abbreviated MDRD equation= 186 * (serum creatinine)^(-1.154) * (age in years)^(-0.203) * (0.742 if female) * (1.210 if black). A normal GFR is >90 mL/min/1.73 m^2, although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR <15 mL/min/1.73 m^2 indicated kidney failure.
Query!
Timepoint [14]
0
0
Month 1, 3, 6, 9, 12
Query!
Secondary outcome [15]
0
0
Number of Participants With Clinically Significant Infections
Query!
Assessment method [15]
0
0
Clinically significant infection was defined as the presence of documented infection confirmed by culture, biopsy, genomic, or serologic findings post-randomization and requiring hospitalization or parenteral anti-infective treatment, or otherwise deemed significant by the investigator.
Query!
Timepoint [15]
0
0
Baseline up to Month 12
Query!
Secondary outcome [16]
0
0
36-Item Short-Form Health Survey (SF-36)
Query!
Assessment method [16]
0
0
SF-36: standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects can also be summarized as physical and mental component scores. Total of 11 variables were analyzed (8 subscales,2 composite subscales and Question(Q) 2 "how would you rate your health in general now?"(range 1=better, 5=worst). The score for a section (except Q2) is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Query!
Timepoint [16]
0
0
Baseline, Month 6, 12
Query!
Secondary outcome [17]
0
0
End-Stage Renal Disease Symptom Checklist Transplantation Module (ESRD-SCL)
Query!
Assessment method [17]
0
0
ESRD-SCL:43-item disease specific self-administered questionnaire. Participants' rated question"At the moment,how much do you suffer?"for each item on 5 point scale,ranged (Ra) 0(not at all)to 4(extremely).Consisted of 6 subscales:cardiac and renal dysfunction;Ra 0-28,increased(In) growth of gum and hair;Ra 0-20,limited cognitive capacity;Ra 0-32,limited physical capacity;Ra 0 - 40,side effects (SEs) of corticosteroids;Ra 0-20,transplantation associated psychological distress(TAPD);Ra 0-32(higher scores=greater dysfunction for each subscale).Total score:0-172,higher scores=greater dysfunction.
Query!
Timepoint [17]
0
0
Baseline, Month 6, 12
Query!
Secondary outcome [18]
0
0
Severity of Dyspepsia Assessment (SODA)
Query!
Assessment method [18]
0
0
SODA:17-item health scale, assessed participant-reported perceptions of dyspepsia;consists of 3 subscales:Pain Intensity (6-items to assess pain and intensity of abdominal [Ab] discomfort; Range (Ra):2-47, higher score= greater pain and Ab discomfort), Non-Pain Symptoms (7-items to assess severity and impact of non-pain symptoms:burping/belching,heartburn,bloating,flatulence,sour taste,nausea,and bad breath; Ra:7-35,higher scores = increased symptom severity and influence), and Satisfaction (4-items to assess degree of satisfaction with Ab discomfort; Ra:2-23,higher scores= more satisfaction).
Query!
Timepoint [18]
0
0
Baseline, Month 6, 12
Query!
Eligibility
Key inclusion criteria
- Recipient of a first-time kidney transplant
- Between the ages of 18 and 70 years, inclusive
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
70
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Recipient of any non-kidney transplant
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/08/2007
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/04/2010
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
338
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Query!
Recruitment hospital [1]
0
0
Pfizer Investigational Site - Camperdown
Query!
Recruitment hospital [2]
0
0
Pfizer Investigational Site - Westmead
Query!
Recruitment hospital [3]
0
0
Pfizer Investigational Site - Adelaide
Query!
Recruitment hospital [4]
0
0
Pfizer Investigational Site - Woodville
Query!
Recruitment hospital [5]
0
0
Pfizer Investigational Site - Clayton
Query!
Recruitment hospital [6]
0
0
Pfizer Investigational Site - Parkville
Query!
Recruitment postcode(s) [1]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [2]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [3]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [4]
0
0
5011 - Woodville
Query!
Recruitment postcode(s) [5]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [6]
0
0
3050 - Parkville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arkansas
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Connecticut
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Maryland
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Massachusetts
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Michigan
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Minnesota
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Missouri
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
New Jersey
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
New York
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
North Carolina
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Oregon
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Pennsylvania
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
South Carolina
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Texas
Query!
Country [19]
0
0
Belgium
Query!
State/province [19]
0
0
Anderlecht
Query!
Country [20]
0
0
Belgium
Query!
State/province [20]
0
0
Leuven
Query!
Country [21]
0
0
Brazil
Query!
State/province [21]
0
0
RS
Query!
Country [22]
0
0
Brazil
Query!
State/province [22]
0
0
SP
Query!
Country [23]
0
0
Canada
Query!
State/province [23]
0
0
Alberta
Query!
Country [24]
0
0
Czech Republic
Query!
State/province [24]
0
0
Praha 4
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Nantes
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Paris Cedex 15
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Toulouse Cedex 9
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Vandoeuvre Les Nancy
Query!
Country [29]
0
0
Germany
Query!
State/province [29]
0
0
Berlin
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Hamburg
Query!
Country [31]
0
0
Italy
Query!
State/province [31]
0
0
Bologna
Query!
Country [32]
0
0
Italy
Query!
State/province [32]
0
0
Roma
Query!
Country [33]
0
0
Korea, Republic of
Query!
State/province [33]
0
0
Seoul
Query!
Country [34]
0
0
Netherlands
Query!
State/province [34]
0
0
Rotterdam
Query!
Country [35]
0
0
Norway
Query!
State/province [35]
0
0
Oslo
Query!
Country [36]
0
0
Poland
Query!
State/province [36]
0
0
Warszawa
Query!
Country [37]
0
0
Poland
Query!
State/province [37]
0
0
Wroclaw
Query!
Country [38]
0
0
Portugal
Query!
State/province [38]
0
0
Coimbra
Query!
Country [39]
0
0
Portugal
Query!
State/province [39]
0
0
Lisboa
Query!
Country [40]
0
0
Spain
Query!
State/province [40]
0
0
Barcelona
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Pfizer
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
A new immunosuppressive drug, based on the inhibition of an important enzyme in the immune
system called JAK3, is being developed by Pfizer to prevent transplant rejection. In this
research study, a JAK3 inhibitor or cyclosporine will be given to new kidney transplant
patients for 12 months. Patients will be assigned to one of three treatment groups after
receiving a kidney transplant. Two of the treatment groups will receive 2 different dosing
regimens of the JAK3 inhibitor that will be taken by mouth. The third treatment group will be
a standard-of-care control arm. Patients will continue to take the assigned study medication
for 12 months as well as other standard transplant medications such as prednisone.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00483756
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Pfizer CT.gov Call Center
Query!
Address
0
0
Pfizer
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00483756
Download to PDF